Conference report: "Functional glycomics in HIV type 1 vaccine design" workshop report, Bethesda, Maryland, April 30-May 1, 2012

AIDS Research and Human Retroviruses

Volumn 29, Issue 11, 2013, Pages 1407-1417

  Malaspina, Angela ^a   Collins, Brenda S ^b   Dell, Anne ^c   Alter, Galit ^d   Onami, Thandi M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; THREONINE;

ANTIBODY RESPONSE; CONFERENCE PAPER; GLYCOBIOLOGY; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNOBIOLOGY; INFECTION PREVENTION; PRIORITY JOURNAL; UNITED STATES; VIRUS ENVELOPE; VIRUS TRANSMISSION;

AIDS VACCINES; GLYCOMICS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84886666326     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0102     Document Type: Conference Paper

References (96)

1. Committee on Assessing the Importance and Impact of Glycomics and Glycosciences: Transforming Glycoscience: A Roadmap for the Future. The National Academies Press, Washington, DC, 2012.
2. Varki A: Evolutionary forces shaping the Golgi glycosylation machinery: Why cell surface glycans are universal to living cells. Cold Spring Harb Perspect Biol 2011; 3(6): a005462.
3. Varki A, et al: Essentials of Glycobiology, 2nd ed, Vol. 784. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2009.
4. Pejchal R, et al.: A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011; 334(6059): 1097-1103.
5. Song X, et al.: Shotgun glycomics: A microarray strategy for functional glycomics. Nat Methods 2011; 8(1): 85-90.
6. Wang Y, et al.: Platelet biogenesis and functions require correct protein O-glycosylation. Proc Natl Acad Sci USA 2012; 109(40): 16143-16148.
7. Macnaughtan MA, et al.: NMR structural characterization of substrates bound to N-acetylglucosaminyltransferase V. J Mol Biol 2007; 366(4): 1266-1281.
8. Van Den Berg LM and Geijtenbeek TB: Antiviral immune responses by human Langerhans cells and dendritic cells in HIV-1 infection. Adv Exp Med Biol 2013; 762: 45-70.
9. Barb AW, et al.: NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry 2012; 51(22): 4618-4626.
10. North SJ, et al.: Mass spectrometry in the analysis of Nlinked and O-linked glycans. Curr Opin Struct Biol 2009; 19(5): 498-506.
11. Go EP, et al.: Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J Virol 2011; 85(16): 8270-8284.
12. Go EP, et al.: Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins. J Proteome Res 2013; 12(3): 1223-1234.
13. Plotkin SA: Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17(7): 1055-1065.
14. Amanna IJ and Slifka MK: Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology 2011; 411(2): 206-215.
15. Korber B, et al.: Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001; 58: 19-42.
16. Scheid JF, et al.: Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011; 333(6049): 1633-1637.
17. Wu X, et al.: Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011; 333(6049): 1593-1602.
18. Walker LM, et al.: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326(5950): 285-289.
19. Walker LM, et al.: Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477(7365): 466-470.
20. Corti D, et al.: Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010; 5(1): e8805.
21. Bonsignori M, et al.: Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 2011; 85(19): 9998-10009.
22. Falkowska E, et al.: PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J Virol 2012; 86(8): 4394-4403.
23. Klein F, et al.: Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med 2012; 209(8): 1469-1479.
24. Zhou T, et al.: Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010; 329(5993): 811-817.
25. Huang J, et al.: Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012; 491(7424): 406-412.
26. Kwong PD, Mascola JR, and Nabel GJ: Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med 2011; 1(1): a007278.
27. McLellan JS, et al.: Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011; 480(7377): 336-343.
28. Moore PL, et al.: Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol 2011; 85(7): 3128-3141.
29. Zolla-Pazner S and Cardozo T: Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol 2010; 10(7): 527-535.
30. Gorny MK, et al.: Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure. PLoS One 2011; 6(12): e27780.
31. Calarese DA, et al.: Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003; 300(5628): 2065-2071.
32. Kwong PD and Mascola JR: Human antibodies that neutralize HIV-1: Identification, structures, and B cell ontogenies. Immunity 2012; 37(3): 412-425.
33. Moore PL, et al.: Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 2012; 18(11): 1688-1692.
34. Mao Y, et al.: Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat Struct Mol Biol 2012; 19(9): 893-899.
35. Pancera M, et al.: Crystal structure of PG16 and chimeric dissection with somatically related PG9: Structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 2010; 84(16): 8098-8110.
36. Pejchal R, et al.: Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci USA 2010; 107(25): 11483-11488.
37. Pancera M, et al.: Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 2013; 20(7): 804-813.
38. Zhu J, et al.: Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. Proc Natl Acad Sci USA 2013; 110(16): 6470-6475.
39. Yu B, et al.: Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials. PLoS One 2012; 7(8): e43903.
40. Gregory T, et al.: Structure and function in recombinant HIV- 1 gp120 and speculation about the disulfide bonding in the gp120 homologs of HIV-2 and SIV. Adv Exp Med Biol 1991; 303: 1-14.
41. Doores KJ, et al.: Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci USA 2010; 107(31): 13800-13805.
42. Bonomelli C, et al.: The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 2011; 6(8): e23521.
43. Crooks ET, et al.: Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J Virol 2011; 85(12): 5825-5839.
44. Morelle W and Michalski JC: Glycomics and mass spectrometry. Curr Pharm Des 2005; 11(20): 2615-2645.
45. Mann M and Jensen ON: Proteomic analysis of posttranslational modifications. Nat Biotechnol 2003; 21(3): 255-261.
46. Trkola A, et al.: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996; 70(2): 1100-1108.
47. Calarese DA, et al.: Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci USA 2005; 102(38): 13372-13377.
48. Astronomo RD, et al.: A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120. J Virol 2008; 82(13): 6359-6368.
49. Wang SK, et al.: Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci USA 2008; 105(10): 3690-3695.
50. Luallen RJ, et al.: A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN. J Virol 2009; 83(10): 4861-4870.
51. Luallen RJ, et al.: Antibodies against Manalpha1, 2- Manalpha1, 2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains. Glycobiology 2010; 20(3): 280-286.
52. Astronomo RD, et al.: Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem Biol 2010; 17(4): 357-370.
53. Dunlop DC, et al.: Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology 2010; 20(7): 812-823.
54. Huber M, et al.: Very few substitutions in a germ line antibody are required to initiate significant domain exchange. J Virol 2010; 84(20): 10700-10707.
55. Doores KJ, et al.: Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged. J Virol 2010; 84(20): 10690-10699.
56. Woods RJ and Tessier MB: Computational glycoscience: Characterizing the spatial and temporal properties of glycans and glycan-protein complexes. Curr Opin Struct Biol 2010; 20(5): 575-583.
57. Ernst B and Magnani JL: From carbohydrate leads to glycomimetic drugs. Nat Rev Drug Discov 2009; 8(8): 661-677.
58. Li Y, et al.: Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 2008; 82(2): 638-651.
59. Anthony RM and Nimmerjahn F: The role of differential IgG glycosylation in the interaction of antibodies with FcgammaRs in vivo. Curr Opin Organ Transplant 2011; 16(1): 7-14.
60. Lux A and Nimmerjahn F: Impact of differential glycosylation on IgG activity. Adv Exp Med Biol 2011; 780: 113-124.
61. Shields RL, et al.: Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277(30): 26733-26740.
62. Shinkawa T, et al.: The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278(5): 3466-3473.
63. Niwa R, et al.: Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004; 64(6): 2127-2133.
64. Niwa R, et al.: IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 2005; 306(1-2): 151-160.
65. Moldt B, et al.: A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIamediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 2012; 86(11): 6189-6196.
66. Kaneko Y, Nimmerjahn F, and Ravetch JV: Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313(5787): 670-673.
67. Forthal DN, et al.: Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007; 178(10): 6596-6603.
68. Forthal DN and Moog C: Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009; 4(5): 388-393.
69. Forthal DN, et al.: IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation. AIDS 2011; 25(17): 2099-2104.
70. Ackerman ME, Dugast AS, and Alter G: Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. Annu Rev Med 2012; 63: 113-130.
71. Alter G and Altfeld M: NK cells in HIV-1 infection: Evidence for their role in the control of HIV-1 infection. J Intern Med 2009; 265(1): 29-42.
72. Isitman G, Stratov I, and Kent SJ: Antibody-dependent cellular cytotoxicity and NK cell-driven immune escape in HIV infection: Implications for HIV vaccine development. Adv Virol 2012; 2012: 637208.
73. Ackerman ME, et al.: Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest 2013; 123(5): 2183-2192.
74. Derdeyn CA, et al.: Envelope-constrained neutralizationsensitive HIV-1 after heterosexual transmission. Science 2004; 303(5666): 2019-2022.
75. Chohan B, et al.: Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J Virol 2005; 79(16): 10701-10708.
76. Keele BF, et al.: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105(21): 7552-7557.
77. Zhang M, et al.: Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 2004; 14(12): 1229-1246.
78. Frost SD, et al.: Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 2005; 102(51): 18514-18519.
79. Gray ES, et al.: N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J Virol 2007; 81(19): 10769-10776.
80. Asmal M, et al.: A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivity. PLoS One 2011; 6(8): e23673.
81. Pinter A, et al.: The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. J Virol 2005; 79(11): 6909-6917.
82. Krachmarov C, et al.: Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities. J Virol 2011; 85(20): 10730-10740.
83. Tong T, et al.: HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. J Virol 2012; 86(7): 3574-3587.
84. Kreisman LS and Cobb BA: Infection, inflammation and host carbohydrates: A glyco-evasion hypothesis. Glycobiology 2012; 22(8): 1019-1030.
85. van Kooyk Y and Rabinovich GA: Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol 2008; 9(6): 593-601.
86. Parker RB and Kohler JJ: Regulation of intracellular signaling by extracellular glycan remodeling. ACS Chem Biol 2010; 5(1): 35-46.
87. Rabinovich GA, van Kooyk Y, and Cobb BA: Glycobiology of immune responses. Ann NY Acad Sci 2012; 1253: 1-15.
88. Selman MH, et al.: Changes in antigen-specific IgG1 Fc Nglycosylation upon influenza and tetanus vaccination. Mol Cell Proteomics 2012; 11(4): M111 014563.
89. Guo N, et al.: Repeated immunization induces the increase in fucose content on antigen-specific IgG N-linked oligosaccharides. Clin Biochem 2005; 38(2): 149-153.
90. Lastra GC, et al.: Changes in the galactose content of IgG during humoral immune responses. Autoimmunity 1998; 28(1): 25-30.
91. Forthal DN, et al.: Fc-glycosylation influences Fcgamma receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol 2010; 185(11): 6876-6882.
92. Yewdell JW and Hill AB: Viral interference with antigen presentation. Nat Immunol 2002; 3(11): 1019-1025.
93. Lilley BN and Ploegh HL: Viral modulation of antigen presentation: Manipulation of cellular targets in the ER and beyond. Immunol Rev 2005; 207: 126-144.
94. Hansen TH and Bouvier M: MHC class I antigen presentation: Learning from viral evasion strategies. Nat Rev Immunol 2009: 9(7): 503-513.
95. Li H, et al.: Proximal glycans outside of the epitopes regulate the presentation of HIV-1 envelope gp120 helper epitopes. J Immunol 2009; 182(10): 6369-6378.
96. Ryan SO and Cobb BA: Host glycans and antigen presentation. Microbes Infect 2012; 14(11): 894-903. Diseases